|
See related Regpara film-coated tab information |
|
|
|
Manufacturer |
Kyowa Hakko Kirin |
|
Distributor |
Hong Kong: LF Asia/Macau: Four Star |
|
Contents |
Cinacalcet HCl |
|
Indications |
Secondary hyperparathyroidism in patients undergoing maintenance dialysis. |
|
Dosage |
Initially 25 mg once daily, may be adjusted to 25-75 mg once daily. Increase dose by 25 mg at 3-wk intervals up to 100 mg once daily if required or if there is no improvement on the parathyroid hormone (PTH). |
|
Administration |
May be taken with or without food (May be taken w/ meals for better absorption.). |
|
Special Precautions |
Determine serum Ca & PTH level prior to & periodically during therapy. Decrease dose as needed if serum Ca level is ≤8.4 mg/dL or w/draw if ≤7.5 mg/dL. Hypocalcemia, seizure, hepatic dysfunction. Pregnancy & lactation. Low birthwt infant, childn. |
|
Adverse Drug Reactions |
GI disturbances, hypocalcemia, prolonged QT interval, decreased level or temporary loss of consciousness.
View ADR Monitoring Form |
|
Drug Interactions |
Azole antifungals, macrolides, amiodarone HCl, grapefruit juice, TCAs, butyrophenone antipsychotics, flecainide, vinblastine, calcitonin, bisphosphonates, corticosteroids, digitoxin, diazepam.
View more drug interactions with Regpara |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
ATC Classification |
H05BX01 - cinacalcet ; Belongs to the class of other anti-parathyroid agents. Used in the management of calcium homeostasis. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Regpara film-coated tablet |
|
|
|
Manufacturer: |
Kyowa Hakko Kirin |
|
Distributor: |
Hong Kong: LF Asia
Macau: Four Star |
|
|
|
|
|
